June 30, 2021 11:17 AM 25 seconds read

Alpine Immune Sciences Initiates Trial Collaboration With Merck

by Vandana Singh Benzinga Editor
Follow
Comments
  • Alpine Immune Sciences Inc ALPN has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc MRK. 
  • This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202 in combination with Merck's Keytruda (pembrolizumab) in patients with advanced malignancies.
  • Dubbed as NEON-2, the trial is currently enrolling.
  • Price Action: ALPN shares are down 1.93% at $8.92 during the market session on the last check Wednesday.
MRK Logo
MRKMerck & Co Inc
$89.061.67%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum17.43
Growth98.14
Quality74.31
Value15.98
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsHealth CareContractsGeneralBriefs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved